3-[[4-[1-[1-(3-Methylphenyl)pyrazol-4-yl]oxybutyl]benzoyl]amino]propanoic acid | 1355534-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[[4-[1-[1-(3-Methylphenyl)pyrazol-4-yl]oxybutyl]benzoyl]amino]propanoic acid
• CAS: 1355534-00-7
• 化学式: C₂₄H₂₇N₃O₄
• 分子量: 421.496
• InChiKey: AESZMKKULCOPFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl 4-(1-hydroxybutyl)benzoate 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 copper(l) iodide 、 O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 水 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 乙酰氯 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 85.0h， 生成 3-[[4-[1-[1-(3-Methylphenyl)pyrazol-4-yl]oxybutyl]benzoyl]amino]propanoic acid
  参考文献：
  名称：

  A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

  摘要：

  A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in compounds 44 and 50 that were shown to have good pharmacokinetic attributes in dog, in contrast to rats, in which clearance was high; and compound 49, which demonstrated a dose-dependent reduction in glucose excursion in a rat glucagon challenge experiment. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.113

文献信息

• A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity
  作者：Kevin J. Filipski、Jianwei Bian、David C. Ebner、Esther C.Y. Lee、Jian-Cheng Li、Matthew F. Sammons、Stephen W. Wright、Benjamin D. Stevens、Mary T. Didiuk、Meihua Tu、Christian Perreault、Janice Brown、Karen Atkinson、Beijing Tan、Christopher T. Salatto、John Litchfield、Jeffrey A. Pfefferkorn、Angel Guzman-Perez

  DOI：10.1016/j.bmcl.2011.10.113

  日期：2012.1

  A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in compounds 44 and 50 that were shown to have good pharmacokinetic attributes in dog, in contrast to rats, in which clearance was high; and compound 49, which demonstrated a dose-dependent reduction in glucose excursion in a rat glucagon challenge experiment. (C) 2011 Elsevier Ltd. All rights reserved.